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Several studies suggest that curcumin and related compounds possess antioxidant and anti-inﬂammatory properties including
modulation of lipopolysaccharide- (LPS-) mediated signalling in macrophage cell models. We here investigated the eﬀects
of curcumin and the two structurally unrelated analogues GG6 and GG9 in primary human blood-derived macrophages as
well as the signalling pathways involved. Macrophages diﬀerentiated from peripheral blood monocytes for 7 days were activated
with LPS or selective Toll-like receptor agonists for 24 h. The eﬀects of test compounds on cytokine production and
immunophenotypes evaluated as CD80+/CCR2+ and CD206+/CD163+ subsets were examined by ELISA and ﬂow cytometry.
Signalling pathways were probed by Western blot. Curcumin (2.5–10μM) failed to suppress LPS-induced inﬂammatory
responses. While GG6 reduced LPS-induced IκB-α degradation and showed a trend towards reduced interleukin-1β release,
GG9 prevented the increase in proinﬂammatory CD80+ macrophage subset, downregulation of the anti-inﬂammatory CD206+/
CD163+ subset, increase in p38 phosphorylation, and increase in cell-bound and secreted interleukin-1β stimulated by LPS, at
least in part through signalling pathways not involving Toll-like receptor 4 and nuclear factor-κB. Thus, the curcumin analogue
GG9 attenuated the LPS-induced inﬂammatory response in human blood-derived macrophages and may therefore represent an
attractive chemical template for macrophage pharmacological targeting.
1. Introduction
A key feature of macrophages is the ability to “tailor” their
responses according to environmental stimuli. Inﬂammatory
agents such as lipopolysaccharide (LPS) and interferon-γ
(IFN-γ) induce an inﬂammatory phenotype that promotes
TH1 eﬀector response and antimicrobial and tumouricidal
properties. LPS/IFN-γ-activated cells are eﬃcient producers
of eﬀector molecules (reactive nitrogen and oxygen interme-
diates) and proinﬂammatory cytokines, such as interleukin-6
(IL-6), IL-1β, and tumour necrosis factor-α, while also
inducing upregulation of molecules associated with antigen
presentation, such as major histocompatibility complex class
II and the costimulatory molecules CD40, CD80, and CD86
[1]. Macrophages with this phenotype are called “classically
activated” macrophages or M1. In contrast, stimulation of
macrophages with cytokines such as IL-4 or IL-13 leads to
an “alternative” activation state or M2, characterized by low
levels of inﬂammatory cytokines such as IL-12 and IL-23,
and high levels of the anti-inﬂammatory cytokine IL-10 as
well as of scavenger, galactose-type, and mannose receptors
(MR or CD206). In general, IL-4/IL-13-activated cells take
part in polarized Th2 responses, parasite clearance, dampen-
ing of inﬂammation, promotion of tissue remodelling,
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angiogenesis, tumour progression, and immunoregulation
[2]. Speciﬁc macrophage-targeted therapies are now being
moved into clinical investigations. In addition, therapeutic
approaches not originally designed as macrophage-oriented
or speciﬁc aﬀect macrophage activation and polarization [3].
Therefore, it is relevant to identify pharmacological agents
aﬀecting the functional activation of human macrophages.
The polyphenol curcumin, the principal bioactive com-
ponent found in the rhizomes of Curcuma longa L., an Asian
tropical plant belonging to the ginger family (Zingiberaceae),
has long been studied for its various therapeutic properties
[4, 5]. The presence of the trans-α,β-unsaturated carbonyl
scaﬀold (referred as hepta-1,4,6-trien-3-one structural
motif), being a Michael acceptor system, is thought to be
involved in its mechanism of action [6]. This compound
can modulate multiple signalling molecules such as tran-
scription factors, enzymes, and secondary messengers,
thereby controlling expression of a variety of genes, and is
potentially eﬀective in disease conditions associated with
impaired regulation of such signalling pathways [7]. In par-
ticular, curcumin reduces LPS-induced activation and release
of inﬂammatory cytokines by microglia and macrophages
[8–13]. We and others demonstrated that curcumin and
related compounds prevent activation of nuclear factor-κB
(NF-κB), a transcriptional factor that regulates many genes
involved in the initiation of inﬂammatory responses [13, 14].
This polyphenol also aﬀects the immunophenotype of
LPS-activated human THP-1 macrophages, especially the
expression of M1 markers that are modulated through the
NF-κB pathway [10, 15]. Interestingly, curcumin not only
directly induces polarization of murine RAW264.7 macro-
phages to the M2 phenotype but also promotes a M1-to-M2
phenotype switch [16]. More recently, Gao et al. [17] demon-
strated that curcumin induces macrophage M2 polarization
by increasing the production of IL-4 and/or IL-13 in a signal
transducers and activators of transcription 6-dependent
manner. These ﬁndings have been also replicated in vivo
in experimental models of disease [17, 18]. Based on these
observations, curcumin and its analogues represent prom-
ising lead compounds targeting immune cell activation.
Toll-like receptors (TLRs) are a family of transmembrane
proteins that play a key role in the innate immune system.
TLRs generally exist as homodimers (although TLR2–TLR6
and TLR1-TLR2 heterodimers have been reported) and are
found on immune cells including macrophages. Ten human
TLRs have been identiﬁed to date, all of which are expressed
in human macrophages at the cell surface or in endosomes
[19]. LPS signalling is mediated mainly by TLR4-MD-2 acti-
vation and dimerization [20]. Previous studies demonstrated
its inhibition by curcumin and its structurally related
bisdemethoxycurcumin (GG6), both carrying the hepta-
1,4,6-trien-3-one scaﬀold, whereas the GG6-based pyrazole
analogue (GG9) was inactive [13].
This extensive body of literature dealing with the phar-
macological eﬀects of curcumin and analogues on immune
cell function has, to the best of our knowledge, not been
extended to human blood-derived macrophages. This may
be relevant due to diﬀerences between rodent and human
immune responses as well as among the many macrophage
cell models used [21, 22]. In addition, poor bioavailability,
rapid metabolism, and adverse eﬀects of curcumin observed
in some studies [23, 24] have provided the impetus for
developing curcumin-based analogues with improved phar-
macodynamic and pharmacokinetic properties [25]. The
present study was designed to investigate the eﬀects of
curcumin and the curcumin-based analogues GG6 and
GG9 [13] on IL-1β release by activated human monocyte-
derived macrophages as well as on the signalling pathways
involved. The eﬀects of GG9 on macrophage immunophe-
notypic marker expression and cell-bound IL-1β were also
examined by ﬂow cytometry.
2. Materials and Methods
2.1. Materials. RPMI 1640 was purchased from Lonza
(Basel, Switzerland), and antibiotic solution (100U/ml
penicillin and 100μg/ml streptomycin) was from Invitrogen
Inc. (Carlsbad, CA, US). Monoclonal anti-human IκB-α,
phospho-p38 mitogen-activated protein kinase (MAPK),
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
antibodies were from Cell Signalling (Danvers, MA, US).
Horseradish peroxidase-conjugated secondary antibodies
were from Vector (Peterborough, UK). Anti-CCR2 mAb,
anti-CD163 mAb, anti-IL-1β mAb, brefeldin, Fix, and Perm
buﬀer solutions were from eBioscience/Aﬀymetrix (Santa
Clara, CA, US); anti-CD80 mAb and anti-CD206 mAb were
from BD Biosciences Pharmigen (San Diego, CA, US). The
cOmplete™ inhibitor cocktail was from Roche Diagnostics
(Mannheim, Germany). Fetal bovine serum (FBS), Ficoll-
Paque (density 1.077± 0.001), Percoll, dexamethasone, cur-
cumin, CLI-095, skim milk powder as well as other analytic
grade chemical agents were from Sigma-Aldrich. Ultrapure
LPS (LPS-EB), zymosan (ZYMO), Pam3CSK4, and Poly(I:C)
were from InvivoGen (San Diego, CA, USA). IL-4, IL-13, and
colony stimulating factor-1 (CSF-1) were from Immuno-
Tools (Friesoythe, Germany). The curcumin analogues
GG6 and GG9 were synthesized as described elsewhere [13].
2.2. Cell Culture. Human peripheral mononuclear cells
(PBMCs) were isolated from deidentiﬁed buﬀy coats pro-
vided by the Transfusion Unit at Padua University Hospital.
After Ficoll separation, PBMCs were separated using a
Percoll density gradient to obtain pure monocytes. The sepa-
ration of monocytes from lymphocytes was performed with a
high-density hyperosmotic Percoll density gradient: the
PBMC suspension, containing 150–200× 106 cells, was lay-
ered on top in a 1 : 3.33ml ratio. After centrifugation at
600g for 15min, cells at the interface were collected and
washed with serum-free RPMI 1640, counted, and seeded
in 24- or 48-well plates or 60mm dishes as indicated at
a density of 5× 104 cells/cm2 in RPMI 1640+10% FBS in
the presence of 20 nM CSF-1 [26]. Cells were cultured
over 7 days at 37°C and 5% CO2, and the medium was
changed every 3 days, added freshly.
2.3. Protocols of Polarized Activation. At the end of diﬀer-
entiation, macrophages seeded in 60mm dishes were washed
and polarized towards either theM1 phenotype by incubation
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with LPS (100 ng/ml) or theM2phenotype by incubationwith
IL-4 (20 ng/ml) + IL-13 (5 ng/ml), respectively, for 24 h in
RPMI+10% FBS as described [27]. It should be pointed out
that commercial sources of LPS are frequently contaminated
by other bacterial components, such as lipoproteins, capable
of activating also TLR2. In contrast, Ultrapure LPS-EB used
here (InvivoGen) only activates TLR4. Test compounds at
concentrations used previously (7.5μM curcumin, 2.5 and
7.5μMGG9, 7.5μMGG6, or 1μMCLI-095) [13] were added
30min before polarized activation. In selected experiments,
unstimulated (M0) macrophages were challenged for 24 h
with either 100nM dexamethasone or 7.5μMGG9.
2.4. Immunophenotyping. At the end of activation, macro-
phages were harvested by gently scraping culture plates with
phosphate-buﬀered saline (PBS) containing 5mM EDTA,
collected in round-bottom tubes for immunolabeling (BD
Biosciences) and resuspended at 106/ml in 100μl PBS with
2% FBS to block Fc receptors. Purity in these cultures was
ﬁrst assessed by staining cells with PE-anti-CD14 (20μl/106
cells). Macrophages were stained for 30min in the dark with
ﬂuorochrome-tagged monoclonal antibodies against surface
CD80-FITC (20μl/106 cells) and CCR2-APC (10 μl/105 cells)
to identify the M1 phenotype and against CD206-FITC
(20μl/106 cells) and CD163-PE (20μl/106 cells) to character-
ize the M2 phenotype [27–29]. After incubation, samples
were washed and suspended in 250μl PBS/EDTA, and
10,000 events/sample for each tube were recorded using
a FacsCanto II ﬂow cytometer (BD Biosciences). Data
were analyzed using FacsDiva software (BD Biosciences).
Isotype-matched controls were used as a reference.
2.5. Intracellular Cytokine Production. Intracellular cytokine
production was also evaluated using ﬂow cytometry. After
CSF-1 diﬀerentiation, macrophages were stimulated with
LPS (100 ng/ml) or other TLR ligands such as zymosan
(10μg/ml), Pam3CSK4 (0.3μg/ml), and Poly(I:C) (50μg/
ml) for 24h in RPMI+10% FBS. Brefeldin (10μM) was
added during the last 4 h to disrupt cytokine secretion. At
the end of stimulation, cells were harvested by gently scrap-
ing the culture plates with 1ml PBS containing 5mM EDTA
and 2% FBS, ﬁxed with 100μl 4% paraformaldehyde solution
and permeabilized by adding 2ml Perm Buﬀer solution con-
taining 0.1% saponin and 0.009% sodium azide. Cells were
centrifuged twice at 300g for 5min and incubated in 100μl
Perm Buﬀer solution in the presence of FITC-anti-IL-1β
(5μl/106 cells) for 20min in the dark. Subsequently, cells
were washed and resuspended in 250μl PBS/EDTA, and
10,000–50,000 events/sample for each tube were recorded.
2.6. Western Blot. After polarized activation in 60mm dishes,
cells were washed once with PBS and harvested in 150μl lysis
buﬀer (50mM Tris HCl pH7.4, 150mM NaCl, 1% NP-40,
25mM NaF, 0.5% Na deoxycholate, 10% SDS, 1mM EGTA,
1mM sodium orthovanadate, 10mM sodium pyrophos-
phate, 1mM phenylmethylsulfonylﬂuoride and cOmplete
protease inhibitor cocktail (Roche). Each sample comprised
two pooled plates and was stored at −20°C until further anal-
ysis. Protein lysates were heated at 100°C for 5min to
denature proteins, and 40μg of each sample (protein con-
tent being measured using the Lowry method) was loaded
onto a 10% SDS/polyacrylamide gel and run at 120V for 1 h.
Proteins were then transferred to a polyvinylidene diﬂuoride
membrane, nonspeciﬁc binding sites blocked with 5%milk in
1M Tris HCl pH7.4, 5M NaCl, and 0.1% Tween 20 for 1 h at
room temperature, washed, and then incubated with speciﬁc
primary antibodies against IκB-α, phosphorylated p38
MAPK, and GAPDH (all 1 : 1000). Membranes were incu-
bated with appropriate horseradish peroxidase-conjugated
secondary antibodies (1 : 5000), and immunoreactive bands
were detected using enhanced chemiluminescence. Band
intensities were normalized to GAPDH and measured using
ImageJ software (US National Institutes of Health).
2.7. Immunoﬂuorescence. Macrophages were grown on cov-
erslips in 12-well plates and pretreated for 1 h with 7.5μM
curcumin, GG6, GG9, or 1μM CLI-095 and then stimulated
with 100ng/ml Ultrapure LPS-EB for an additional 90min.
Cells were ﬁxed with 4% paraformaldehyde (pH7.4, for
15min at room temperature) and subsequently blocked with
5% normal goat serum/0.1% Triton X-100 in PBS for 1 h as
described [30]. Cells were incubated with a mouse anti-p65
antibody (NF-κB p65, 1 : 500; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) followed by an Alexa Fluor 555-
conjugated anti-mouse secondary antibody (1 : 1000; Invitro-
gen). Nuclei were stained with 4,6-diamidino-2-phenylindole
(DAPI, Sigma), and coverslips were mounted on microscope
slides with Fluoromount-G mounting medium (Thermo
Fisher Scientiﬁc, Milan, Italy). Fluorescent images for p65
staining were captured with a confocal laser-scanning
microscope (Zeiss LSM 800; Carl Zeiss AG, Oberkochen,
Germany) and analyzed with ZEN 2.0 imaging software
(Carl Zeiss AG).
2.8. Cytokine Release. Monocytes were seeded in 24-well
plates at a density of 106 cells/well and allowed to diﬀerenti-
ate for 7 days as described above. Cells were primed using
1μg/ml LPS in serum-free RPMI for 24h in the presence or
absence of curcumin analogues at concentrations selected
based on preliminary experiments. Cell supernatants were
collected and stored at −20°C until analysis. Cell lysates were
prepared by adding 40μl lysis solution to each well. The
amount of IL-1β in the culture medium and cell lysates was
assessed using a commercially available ELISA kit according
to the manufacturer’s instructions (Antigenix America, Hun-
tington Station, NY, USA). The IL-1β ELISA assay kit does
not distinguish between the inactive 31-kDa precursor
(pro-IL-1β) and the bioactive 17 kDa mature form (as is the
case for all commercially available kits). Standard curves
were used to obtain sample IL-1β concentrations (pg/ml).
2.9. Statistical Analysis. Statistical analysis was performed
using Prism software (GraphPad Software Inc., La Jolla,
CA, US). Data were expressed as mean± SEM. t-test or
ANOVA followed by Bonferroni post hoc test was used for
comparison between samples. A p value< 0.05 was consid-
ered to be statistically signiﬁcant.
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3. Results
3.1. Eﬀects of the Pyrazole Curcumin Analogue (GG9) on
Macrophage Activation Phenotypes.We then performed ﬂow
cytometry experiments to investigate macrophage activation.
The yellow color of curcumin and GG6 solutions interferes
with the ﬂow cytometer laser detection, and so the two com-
pounds were excluded from this set of analyses. Dexametha-
sone (dexa) was used as a reference anti-inﬂammatory agent
based on previous work [27]. The possible eﬀects of GG9 at a
noncytotoxic concentration on immunophenotypes were
compared to those of CLI-095, which blocks signalling medi-
ated by the intracellular but not extracellular domain of TLR4
[31]. Cells were pretreated with dexa (100 nM), CLI-095
(1μM), or GG9 (7.5μM) for 30min, and subsequently incu-
bated for 24 h with fresh medium to obtain resting macro-
phages (M0) or with either LPS or IL-4/IL-13 to obtain
macrophages activated to the M1 and M2 phenotypes,
respectively. Representative cell surface CD80 levels are
shown in Figure 1(a). Treatment with LPS but not with IL-
4/IL-13 for 24 h markedly induced the fraction of cells
expressing the M1 marker CD80 (Figure 1(b)) that was sig-
niﬁcantly suppressed by GG9, dexa, and CLI-095. While
the change in CCR2+ cells induced by LPS was not signiﬁcant
(Figures 1(c) and 1(d)), dexa but not GG9 or CLI-095 signif-
icantly reduced this cell subpopulation compared with rest-
ing cells. Pretreatment with dexa signiﬁcantly prevented the
upregulation of M1 (CD80+/CCR2+) cells induced by LPS
(0.7± 0.3% versus 3.0± 1.0%, p < 0 05, n = 6; Figures 2(a)
and 2(b)), whereas a nonsigniﬁcant trend of inhibition was
observed for GG9 and CLI-095.
We next investigated modulation of the M2 markers
CD163 and CD206 (Figure 3(a)) following activation by
LPS or IL-4/IL-13. As expected, the fraction of CD206+/
CD163+cells was enhanced in the presence of IL-4/IL-13
compared with resting cells (Figure 3(b)). In contrast,
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Figure 1: Eﬀects of GG9, dexamethasone (dexa), and CLI-095 on LPS-induced activation of M1 macrophage markers CD80 and CCR2. Cells
were pretreated with dexa, GG9, and CLI-095 for 30min and then polarized using either 0.1 μMLPS (M1) or 20 ng/ml IL-4 plus 5 ng/ml IL-13
(M2) for 24 h in RPMI + 10% FBS as described in Materials and Methods. (a, c) Representative ﬂow cytometry assays for CD80+ and CCR2+
cells. Bar graphs represent the mean (±SEM) of CD80+ (b) and CCR2+ (d) mean ﬂuorescence intensity (MFI) from 6 independent
experiments. ∗∗p < 0 01 versus resting; #p < 0 05 and ##p < 0 01 versus LPS.
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proinﬂammatory activation with LPS sharply decreased the
fraction of M2 macrophages that was restored by dexa treat-
ment (5.9± 2.0 versus 1.1± 0.4%, n = 5). Similarly, GG9
signiﬁcantly prevented LPS-induced downregulation of
CD206+/CD163+cells (3.4± 1.0 versus 1.1± 0.4%, n = 5;
Figure 3(b)), as did CLI-095 (3.4± 0.8 versus 1.1± 0.4%,
p < 0 05, n = 5). The same pattern was observed in cells
expressing each single M2 marker (data not shown). In
order to assess a possible direct eﬀect of GG9 on M2
polarization, the experiment was repeated in unstimulated
macrophages. Treatment with dexa for 24h signiﬁcantly
increased the percentage of CD206+/CD163+ subpopulations
with respect to untreated macrophages (8.8±2.2 versus 3.4
±0.9%, p < 0 05, n = 6), as previously published by our
group [27]. In contrast, GG9 treatment did not aﬀect the
percentage of CD206+/CD163+ cells (Figure 3(c)).
3.2. Eﬀects of Curcumin, GG6, and GG9 on LPS-Induced
Signalling. We previously reported that curcumin and GG6,
unlike GG9, inhibit LPS-induced activation of NF-κB in pri-
mary rat microglia [13]. However, as shown above, GG9 was
eﬀective in preventing the increase in the costimulatory
molecule CD80, a strong membrane marker of M1 polar-
ization, induced by LPS via transcriptional mechanisms
[15, 32]. To identify potential signalling pathways underlying
the immunophenotype ﬁndings for GG9, we measured IκB-
α degradation that is required for NF-κB transcriptional
activation. In contrast to rat microglia, IκB-α degradation
induced by a 30min challenge with LPS was unchanged by
curcumin (Figure 4). Similarly, pretreatment with GG9 did
not aﬀect this pathway, whereas GG6 and even more so
the inhibitor of TLR4 signal transduction CLI-095 signiﬁ-
cantly increased IκB-α levels compared with LPS alone
(Figure 4(a)). We also assessed LPS-induced translocation
of NF-κB by p65 immunoﬂuorescence and conﬁrmed that
GG6 and CLI-095 were the only compounds aﬀecting the
NF-κB pathway in the cell model used in this study
(Figures 4(b–g)).
Because the p38 kinases are responsive to stresses such as
cytokine stimulation and curcumin inhibits p38 MAPK
phosphorylation in RAW 264.7 murine macrophages [33],
immunodetection of phospho-p38 was performed under
similar conditions. While pretreatment with curcumin and
GG6, sharing the arylhepta-1,4,6-trien-3-one structural
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Figure 2: Eﬀects of GG9, dexamethasone (dexa), and CLI-095 on the M1 macrophage phenotype as deﬁned by CD80+/CCR2+ cells.
Cells were activated and treated as described in the legend of Figure 1. Fluorescence quantiﬁcation dot plots (a) are from a representative
experiment. Bars represent the mean (±SEM) of CD80+/CCR2+cells (b) from 6 independent experiments. ∗p < 0 05 versus resting;
#p < 0 05 versus LPS.
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motif, failed to aﬀect LPS-induced p38 phosphorylation,
pretreatment with GG9 and CLI-095 signiﬁcantly reduced
p-p38 levels (Figure 5). These data demonstrate the
importance of the pyrazole function for the regulation of
LPS signalling in human monocyte-derived macrophages.
3.3. Eﬀects of Test Compounds on IL-1β Production Induced
by TLR Ligands. A functional readout of the anti-LPS eﬀect
on M1 phenotypic markers as shown by GG9 (Figure 1)
is cytokine production. Stimulation of macrophages with
LPS results in increased production of proinﬂammatory
cytokines. This was indeed the case for cell-bound IL-1β
(Figures 6(a) and 6(b)) in LPS-stimulated cells compared
with levels detectable in unstimulated cells as measured
by ﬂow cytometry. LPS-induced cellular accumulation of
IL-1β was signiﬁcantly reduced by pretreatment with both
7.5μM GG9 and 1μM CLI-095 (n = 5; Figure 6(b)).
Because GG9 displayed pharmacological activity on
IL-1β production in human macrophages as opposed to
rat microglia [13], we explored its potential to interfere
with additional TLRs that may involve diﬀerent signalling
pathways. The ﬂow cytometry cell-bound IL-1β assay was
repeated using TLR ligands other than LPS. Zymosan, a yeast
TLR2 and TLR2/TLR6 agonist, markedly increased the IL-
1β+ subpopulation that was signiﬁcantly reduced by about
40% after pretreatment with GG9 (Figure 7). The TLR3 acti-
vator Poly(I:C), a synthetic analogue of double-stranded
RNA, was less eﬀective than the TLR2/TLR1 agonist
Pam3CSK4 in increasing the IL-1β+ subpopulation, which
was unchanged after pretreatment with GG9 in either case
(Figure 7). Conceivably, GG9 could interfere with TLR2 in
the human macrophage inﬂammatory response.
Because the functional eﬀects of curcumin and GG6
could not be tested using ﬂow cytometry, we measured IL-
1β release by LPS-stimulated macrophages (see also [13]).
Basal IL-1β release by CSF-1-diﬀerentiated macrophages in
the absence of inﬂammasome activator was barely detectable
by ELISA (data not shown), consistent with recent studies
[34]. Stimulation with LPS for 24 h signiﬁcantly increased
the release of IL-1β into the medium (39.5± 14.8 pg/ml,
n = 3; Figure 8). Of note, human macrophages release
about 10-fold less IL-1β than primary rat microglia [9], with
noticeable variation among donors. Pretreatment with GG9
and CLI-095 remarkably reduced IL-1β release to less than
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Figure 3: Eﬀects of GG9, dexamethasone (dexa), and CLI-095 on the M2 macrophage phenotype as deﬁned by CD206+/CD163+ cells. Cells
were activated and treated as described in the legend to Figure 1. Fluorescence quantiﬁcation dot plots (a) are from a representative
experiment. (b) Bars represent the mean (±SEM) fraction of CD206+/CD163+ cells after pretreatment with test agents as indicated from 5-
6 independent experiments. (c) Fraction of CD206+/CD163+ resting macrophages following treatment with test agents for 24 h as
indicated. ∗p < 0 05; ∗∗p < 0 005 versus resting; and #p < 0 05 versus LPS.
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10% of the LPS level (Figure 8), in line with data in Figure 6.
In contrast, the trend of GG6 towards attenuation of LPS-
induced IL-1β release did not achieve statistical signiﬁcance,
and curcumin induced no apparent eﬀect.
We analysed in more detail the IL-1β pathway in polar-
ized macrophages by measuring mRNA levels of the NLRP3
inﬂammasome. The signiﬁcant reduction in LPS-induced
cellular accumulation (Figure 6) and release (Figure 8) of
IL-1β following pretreatment with GG9 and CLI was associ-
ated with a trend towards increased NLRP3 mRNA levels
(Figure S3). To support the potential involvement of the
NLRP3 inﬂammasome in GG9 action, we showed that this
agent had no eﬀect on TNF-α cellular accumulation, which
is independent from inﬂammasome activation (Figure S4).
These data suggest that GG6 and GG9 interfere with diﬀeren-
tial and possibly redundant inﬂammatory signalling path-
ways in human macrophages.
4. Discussion
In this study, we investigated whether the eﬀects of the natu-
rally occurring curcuminoids curcumin and bisdemethoxy
curcumin (GG6), together with a pyrazole analogue obtained
by GG6 cyclization, on macrophage immunophenotype and
function as reported in a variety of cell types could be
reproduced in human monocyte-derived macrophages.
Unexpectedly, curcumin was ineﬀective against all study
endpoints, whereas GG6 and GG9 displayed diﬀerential
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Figure 4: (a) IκB-α immunodetection in CSF-1-driven macrophages. Total protein extracts from resting, LPS-stimulated M1, and test agent-
pretreatedM1macrophages were assayed after 30min LPS incubation. GAPDH served as loading control. Bars represent the mean (±SEM) of
4 independent experiments. Results from representative immunoblots are shown. ∗∗p < 0 0005 versus resting; #p < 0 05; and ##p < 0 005
versus LPS. (b–g) Cells were pretreated with curcumin, GG6, GG9, and CLI-095 before stimulation with LPS, and then processed for NF-
κB p65 immunostaining. Representative confocal images showing subcellular localization of p65 in unstimulated and LPS-stimulated
macrophages are shown in (b) and (c), respectively. Treatment with curcumin, GG6, GG9, and CLI-095 are shown in (d–g), respectively.
Arrows indicate representative cells with attenuated p65 staining. Scale bar: 10 μm; magniﬁcation: 63x.
7Mediators of Inﬂammation
pharmacological proﬁles that were only partially consistent
with those observed in primary rat microglia [13].
Although we were unable to test curcumin and GG6
by ﬂow cytometry due to the yellow color of their solu-
tions, GG9 prevented upregulation of CD80 expression
induced by LPS activation [15, 32], thereby attenuating
M1 polarization. The eﬀect of GG9 on the CD80+/CCR2+
subset was, however, not signiﬁcant (Figure 2), as the fraction
of CCR2+ cells was unchanged following LPS activation
(Figure 1(b)). In contrast with previous studies with curcu-
min [17], GG9 had no eﬀect on the M2 phenotype in
unstimulated cells, but counteracted the decrease in the
anti-inﬂammatory CD206+/CD163+ subset induced by
LPS [27, 29]. These ﬁndings suggest that GG9 was able to
interfere with transcriptional mechanisms underlying upreg-
ulation of costimulatory molecules such as CD80, but not
with desensitization and internalization pathways that
largely govern surface levels of G-protein-coupled receptors
such as CCR2 [35]. In contrast, treatment with dexametha-
sone reduced the CD80+/CCR2+ subset and enhanced the
CD206+/CD163+ subset in both LPS-treated and untreated
macrophages (Figures 3(b) and 3(c)). This is consistent
with ﬁndings from several cell models [27, 36, 37], sug-
gesting that dexamethasone, unlike GG9, induces a direct
eﬀect on M2 macrophage polarization.
The mechanisms of pathogen-mediated TLR activation,
signalling, and downstream inﬂammatory responses have
been extensively investigated. The 10 TLRs expressed in
humans either as monomers or through assembly of het-
erodimers signal through MyD88-dependent and MyD88-
independent pathways that converge on activation of
transcription factors. In particular, LPS-mediated activation
of TLR4 in association with MD2 stimulates the phosphory-
lation (and activation) of the MAPKs p38 and c-Jun N-
terminal kinase and activation of NF-κB-dependent gene
transcription [38]. Accordingly, by suppressing speciﬁcally
the signalling mediated by the intracellular but not the extra-
cellular domain of TLR4, CLI-095 restored both LPS-induced
IκB-α degradation and p38 phosphorylation [39]. We
observed that pretreatment with GG9 interfered speciﬁcally
with the p38-MAPK pathway, whereas GG6 signiﬁcantly
prevented IκB-α degradation required for NF-κB activation.
This is consistent with a diﬀerential structure-activity rela-
tionship for the diaryl-hepta-1,4,6-trien-3-one scaﬀold of
GG6 and the pyrazole analogue GG9 described in primary
rat microglia [13], where GG9 does not modulate LPS-
mediated TLR4-MD2 signalling. Here, we demonstrated
diﬀerent pharmacological proﬁles for the two analogues in
disrupting or redirecting LPS signalling in human macro-
phages. In contrast to rat microglia [13] and other cell types
[10, 40–42] where higher concentrations may have been
used, curcumin aﬀected neither LPS-induced signalling nor
IL-1β release in human monocyte-derived macrophages.
This could be due to species diﬀerences in TLR expression
pattern as well as TLR4 and MD2 amino acid similarity and
structural features [43–45], thus resulting in reduced curcu-
min potency in human versus rodent cells. However, the lack
of activity of curcumin compared to its bisdemethoxy-
derivative GG6 remains unexplained. It should be considered
that GG6, due the absence of the methoxy functions peculiar
of curcumin, has a more hydrophilic character compared to
curcumin, as the hydroxyl functions on the side aryl rings
are not involved in intramolecular hydrogen bonding with
the adjacent methoxyls. Hence, this behaviour may account
for a superior chemical stability of GG6 [46].
Functional assay of inhibition of LPS-induced cytokine
production revealed additional diﬀerences in the pharma-
cological proﬁle of GG6 and GG9. Abe et al. [47] ﬁrst
demonstrated that curcumin inhibits inﬂammatory cytokine
production in human peripheral blood monocytes. However,
we were unable to show any such eﬀects of curcumin in mac-
rophages, and the negative trend of GG6 on limiting LPS-
induced IL-1β release did not achieve statistical signiﬁcance.
Human macrophages in the absence of inﬂammasome acti-
vators secrete considerably less IL-1β than primary rat
microglia upon stimulation with LPS [9], thereby making it
more diﬃcult to assess the potential eﬀects of pharmacolog-
ical inhibitors. Furthermore, we were unable to identify any
potential correlation of IL-1β data for GG6 (and curcumin)
with their eﬀects on the M1 immunophenotype because, as
noted above, these compounds were unsuitable for ﬂow cyto-
metric assay. However, although polarized activation proto-
cols are critical in shaping immunophenotype, functional
assays are required when investigating pharmacological
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Figure 5: Phospho-p38-MAPK immunodetection in CSF-1-driven
macrophages. Total protein extracts from resting, untreated M1,
and test agent-pretreated M1 macrophages were assayed after
30min LPS incubation. GAPDH served as loading control. Bars
represent the mean (±SEM) of 6 independent experiments. Results
from representative immunoblots are shown. ∗p < 0 05 versus
resting; #p < 0 05 versus LPS.
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targeting of macrophages. GG9 was as eﬀective as the TLR4
signalling inhibitor CLI-095 in reducing LPS-triggered IL-
1β production, even if GG9 did not aﬀect the NF-κB pathway
activated by TLR4 (LPS; Figure 4) or TLR3 (Poly(I:C) [48])
ligands. Given that IL-1β occurs in cells as both a largely
nonsecreted proform and a cleaved and releasable mature
form [49] and that the p38 MAPK pathway is involved in
IL-1β secretion in humanmacrophages [50], this mechanism
(Figure 5) may account for the observed downregulation of
LPS-stimulated synthesis and release of IL-1β by GG9.
Because the production of IL-1β is regulated by a two-step
mechanism [51], GG9 may also have prevented IL-1β matu-
ration, as described for curcumin in THP-1 cells [12]. To
support the potential involvement of the NLRP3 inﬂamma-
some in GG9 action, we showed that this agent had no eﬀect
on the cell accumulation of TNF-α, which is independent
from inﬂammasome activation [52].
Overall, these results suggest diﬀerential structural inter-
actions of GG6 and GG9 at the receptor level. Our interpre-
tation is that the diaryl-hepta-1,4,6-trien-3-one scaﬀold of
GG6 interfered with LPS-induced signal transduction mainly
via the TLR4/MD2 complex and downstream activation of
NF-κB (Figure 4; see also [13]), whereas GG9 impacted on
partially overlapping, yet distinct, pathways possibly includ-
ing MyD88-independent TLR4 [53] and/or TLR2 signalling
(Figure 7). In fact, GG9 interfered with TLR2/TLR6 signal-
ling that is coupled to p38 MAPK activation [54] and possi-
bly with the calcium-dependent calmodulin-dependent
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Figure 6: Eﬀects of GG9 and CLI-095 on cell-bound IL-1β expression in LPS-stimulated macrophages. After diﬀerentiation, macrophages
were pretreated with either GG9 or CLI-095 for 30min, and then incubated with LPS for 24 h at 37°C in RPMI + 10% FBS in the presence
of brefeldin (10 μM) over the last 4 h to disrupt cytokine secretion pathways. Prior to ﬂow cytometry analysis, ﬁxed/permeabilized cells
were stained with anti-IL-1β antibodies. Fluorescence plots are from representative experiments (a), and bar graphs represent the mean
(±SEM) of 5 independent experiments (b). ∗∗p < 0 01 versus resting; #p < 0 005; and ##p < 0 001 versus LPS.
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Figure 7: Eﬀect ofGG9 onmacrophage cell-bound IL-1β expression
induced by TLR ligands. After diﬀerentiation, macrophages
were pretreated with GG9 for 30min, and then incubated with
zymosan (10 μg/ml), Pam3CSK4 (PAM3, 0.3 μg/ml), and Poly(I:C)
(50 μg/ml) for 24 h at 37°C in RPMI + 10% FBS in the presence of
brefeldin (10 μM) over the last 4 h to disrupt cytokine secretion
pathways. Prior to ﬂow cytometry analysis, ﬁxed/permeabilized
cells were stained with anti-IL-1β antibody. Bar graphs represent
the mean (±SEM) of 4 independent experiments. ∗p < 0 05;
∗∗p < 0 001 versus resting; and #p < 0 05 versus TLR agonist.
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kinase-Pyk2-extracellular signal-regulated kinase signalling
pathway activated by zymosan in human blood-derived mac-
rophages [55]. TLR2 expression is elevated in macrophages
within inﬂamed human tissue [56], and our data support
the relevance of TLR2 in inﬂammatory responses in vivo.
Finally, an intriguing possibility, albeit supported by limited
evidence, is that TLR4 associates with TLR2 to form TLR2-
TLR4 heterodimers [57], which might ﬁnely tune LPS
signalling and possibly expand the ligand spectrum.
5. Conclusion
Collectively, these results support the hypothesis that cur-
cumin derivatives aﬀect human monocyte-macrophage
immunophenotypes and function by disrupting LPS signal-
ling. The two analogues GG6 and GG9, structurally charac-
terized by the same side aryl rings and a diﬀerent core,
showed a diﬀerential pharmacological proﬁle through inhi-
bition of the NF-κB or p38 MAPK pathways, respectively,
possibly resulting from binding to diﬀerent TLR isoforms.
Promoting a macrophage-protective phenotype has become
a therapeutic goal in the treatment of inﬂammatory condi-
tions, and the identiﬁcation of factors that control cell
activation is currently an area of active research. The
present ﬁndings suggest that the curcumin analogues GG6
and GG9 represent promising lead compounds targeting
immune cell activation.
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Supplementary Materials
Supplemental Figure 1: human blood-derived monocytes
were grown in RPMI+10% FBS and diﬀerentiated into mac-
rophages in the presence of 20 nM CSF-1 for 7 days at 37°C
and 5% CO2. At the end of diﬀerentiation, macrophage via-
bility was measured by MTT assay following treatment with
curcumin, GG6, and GG9 (2.5–10μM) for 24h. Data are
expressed as mean raw absorbance values (±SEM) of 3 inde-
pendent experiments performed in triplicate. Supplemental
Figure 2: eﬀects of curcumin, GG6, GG9, and CLI-095 on
IL-1β accumulation in LPS-stimulated human macrophages.
After diﬀerentiation, macrophages were pretreated with
vehicle, curcumin, GG6, GG9, and CLI-095 as indicated for
30min followed by stimulation with 1μg/ml LPS for 24 h in
FBS-free RPMI in the presence of brefeldin (10μM) over
the last 4 h to disrupt cytokine secretion pathways. Cell
lysates were collected and analyzed for IL-1β release by
ELISA. Bar graph represents the mean (±SEM) of 6
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Figure 8: Eﬀects of curcumin, GG6, GG9, and CLI-095 on IL-1β
release from LPS-stimulated human macrophages. After
diﬀerentiation, macrophages were pretreated with curcumin, GG6,
GG9, and CLI-095 as indicated for 30min followed by
stimulation with 1μg/ml LPS for 24 h in FBS-free RPMI.
Supernatants were collected and analyzed for IL-1β release by
ELISA. Bar graph represents the mean (±SEM) of 3 independent
experiments. #p < 0 05 versus LPS.
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independent experiments. #p < 0 05 versus LPS. Supplemen-
tal Figure 3: human NLRP3 mRNA levels in macrophages.
cDNA from resting, LPS-stimulated M1, and test agent-
pretreated M1 macrophages were assayed by qPCR after
90-min LPS incubation. GAPDH served as loading control.
Bars represent the mean (±SEM) of 3 independent experi-
ments. Supplemental Figure 4: eﬀects of GG9 and CLI-095
on cell-bound TNF-α expression in LPS-stimulated macro-
phages. After diﬀerentiation, macrophages were pretreated
with either GG9 or CLI-095 for 30min, and then incubated
with LPS for 6 h at 37°C in RPMI+10% FBS in the presence
of brefeldin (10μM) over the last 4 h to disrupt cytokine
secretion pathways. Prior to ﬂow cytometry analysis, ﬁxed/
permeabilized cells were stained with anti-TNF-α antibodies
(eBioscience). Fluorescence plots are from representative
experiments (panel A), and bar graphs represent the mean
(±SEM) of 5 independent experiments (panel B). ∗p < 0 05
versus resting; #p < 0 05 versus LPS. In preliminary experi-
ments, treatment with curcumin, GG6, or GG9 at concentra-
tions tested in previous work (2.5–10μM) [11, 13] for 24 h
did not compromise viability of human monocyte-derived
macrophages as measured by the MTT assay (Figure S1).
LPS-induced cellular accumulation of IL-1β was signiﬁcantly
reduced by pretreatment with both 7.5μM GG9 and 1μM
CLI-095 as measured by ELISA (Figure S2). This was associ-
ated with a trend towards increased NLRP3 mRNA levels
(Figure S3). In addition, GG9 had no eﬀect on TNF-α cellular
accumulation, which is independent from inﬂammasome
activation (Figure S4). (Supplementary Materials)
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